At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 55 enrolled
Drug / intervention
Dapagliflozin +1 moredrug
Likely dose
Dapagliflozin 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An 8-week, Single Centre, Randomized, Parallel-group, Double-blind, Placebo Controlled Phase IV Study to Evaluate Dapagliflozin 10 mg Once Daily Effects on Insulin Resistance in Subjects With Type 2 Diabetes Mellitus
In Brief
A Phase 4 clinical trial evaluating Dapagliflozin and Placebo for Type 2 Diabetes Mellitus. Completed, enrolled 55 participants across 1 site.
Detailed Summary
This is an 8-week, single centre, randomized, parallel-group, double-blind, placebo-controlled Phase IV study to evaluate the effect of dapagliflozin on tissue specific insulin sensitivity in patients with Type 2 diabetes mellitus
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
CountriesFinland
CollaboratorsAntaros Medical, Bioventure Hub, 43183 Mölndal, Sweden
Timeline
Phase 4CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartMar 2015
First PostedApr 2015
Primary CompletionApr 2016
TodayJul 2026
First PostedApr 27, 2015
Enrollment StartMar 23, 2015
Primary CompletionApr 28, 2016
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 11.2 years ago
Interventions
Dapagliflozindrug
Dapagliflozin 10 mg Tablets, Oral, Once Daily, 8 weeks
Placebodrug
Matching placebo to Dapagliflozin 10 mg Tablets, Oral, Once Daily, 8 weeks